MacroGenics said the U.S. FDA has placed a partial clinical hold on its Phase 2 LINNET trial of lorigerlimab in gynecologic cancers, halting enrollment of new patients while allowing current participants to continue treatment. The action follows the company’s notification of a temporary enrollment pause after recent serious safety events, including Grade 4 thrombocytopenia, myocarditis, neutropenia with septic shock, and one Grade 5 event. MacroGenics said it is working with the FDA to resolve the hold and resume enrollment.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MacroGenics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602231814PRIMZONEFULLFEED9659736) on February 23, 2026, and is solely responsible for the information contained therein.